Ruxolitinib is a small-molecule inhibitor of Janus kinases (JAK1 and JAK2), used as an active pharmaceutical ingredient in pharmaceutical manufacturing. It is characterized by a pyrazole ring substituted with a pyrrolopyrimidine group and a nitrile-containing side chain.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 941678-49-5
(betaR)-beta-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile maleate
research compound
Ruxolitinib phosphate
pharmaceutical raw material
Ruxolitinib hydrochloride
pharmaceutical raw material
Tegoprazan
pharmaceutical raw material
(4R)-Tegoprazan
pharmaceutical raw material
Tolvaptan sodium phosphate
pharmaceutical raw material
Etilefrine hydrochloride
pharmaceutical raw material
(3S)-3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile
pharmaceutical raw material
(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile
HFNKQEVNSGCOJV-OAHLLOKOSA-N
C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3